Monoclonal Antibodies Market for Colorectal Cancer to Witness Moderate Growth, as Late-Stage Pipeline Remains Weak
The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase from $3.7 billion in 2012 to $5.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%, according to a new report from business intelligence provider GBI Research.
The company’s latest report, Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth, states that this moderate growth is due to the slow rise of the prevalent population and weakness of the late-stage pipeline. Currently, there is only one mAb product in Phase III development for the treatment of colorectal cancer, named IMC-1121B.
Dominic Trewartha, Analyst for GBI Research, says “The efficacy of this drug has not yet been proven in large-scale, placebo-controlled Phase III trials, which creates an element of uncertainty in terms of the outcome of these products. As such, this weak late-stage pipeline is not expected to drive market growth to a significant extent during the forecast period.”
The current metastatic colorectal cancer market is dominated by three mAbs – Avastin, Erbitux, and Vectibix – which are far more efficacious than the targeted small molecule therapies also marketed for this setting. Therefore, GBI Research believes there is a strong opportunity for the entry of new mAbs into the market, as long as they prove superior efficacy when compared to Avastin.
Mr. Trewartha says, “A product that can attain first-line status in the treatment of colorectal cancer, or even second-line status by displacing Erbitux and Vectibix, would have access to a considerable patient population and be able to generate a substantial amount of revenue. “Furthermore, there are currently no approved mAbs in the early stage setting for colorectal cancer, reflecting an additional opportunity for the development of new products.”
The report provides in-depth analysis of three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns, and strengths/weaknesses. It also gives a comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure professionals stay up-to-date with the latest emerging trends in their markets. For more information, visit www.gbiresearch.com.
Total Page Views: 1061
